- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06305754
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors
The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs).
The primary hypotheses of this study are that sacituzumab tirumotecan is better than platinum-based doublet chemotherapy (pemetrexed and carboplatin) in regard to progression-free survival (PFS) and overall survival (OS).
Study Overview
Status
Conditions
Detailed Description
Participants will be randomized 1:1 into two arms:
- Sacituzumab tirumotecan
- Pemetrexed plus Carboplatin
Participants will receive treatment until any of the criteria for discontinuation of study intervention are met.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of advanced-stage nonsquamous non-small cell lung cancer (NSCLC).
- Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to Grade <1 or baseline.
- Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load.
- Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable.
- Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy.
- Life expectancy of at least 3 months.
Exclusion Criteria:
- Predominantly squamous cell histology NSCLC.
- History of second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
- Grade >2 peripheral neuropathy.
- History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing.
- Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease.
- Uncontrolled, or significant cardiovascular disease or cerebrovascular disease.
- Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.
- Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
- Received radiation therapy to the lung that is >30 Gray within 6 months of the first dose of study intervention.
- Known active central nervous system metastases and/or carcinomatous meningitis.
- Active infection requiring systemic therapy.
- History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
- Concurrent active HBV and HCV infection.
- History of allogeneic tissue/solid organ transplant.
- Participants who have not adequately recovered from major surgery or have ongoing surgical complications.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Pemetrexed Plus Carboplatin
Participants receive, via IV infusion, 500 mg/m2 pemetrexed every 3 weeks (Days 1 and 22 of every 6-week cycle) plus area under the curve (AUC) 5 mg/mL*min carboplatin every 3 weeks (Days 1 and 22 of every 6-week cycle for 4 doses), then 500 mg/m2 pemetrexed every 3 weeks until discontinuation criteria is met.
|
500 mg/m^2 via IV infusion
AUC 5 mg/mL*min via IV infusion
|
Experimental: Sacituzumab tirumotecan
Participants receive 4 mg/kg sacituzumab tirumotecan via intravenous (IV) infusion every 2 weeks (Days 1, 15, and 29 of every 6-week cycle) until discontinuation criteria is met.
|
Administered as rescue medication per approved product label
Administered as rescue medication per approved product label
Administered as rescue medication per approved product label
Administered as rescue medication per approved product label
4 mg/kg via IV infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS)
Time Frame: Up to approximately 51 months
|
Progression-Free Survival is defined as the time from randomization to the first documented disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review (BICR) or death due to any cause, whichever occurs first.
PFS for all randomized participants will be reported.
|
Up to approximately 51 months
|
Overall Survival (OS)
Time Frame: Up to approximately 51 months
|
Overall survival is defined as the time from randomization to death due to any cause.
Overall survival for all randomized participants will be reported.
|
Up to approximately 51 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Up to approximately 51 months
|
The objective response rate (ORR) is defined as a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by BICR.
The overall response rate for all randomized participants will be reported.
|
Up to approximately 51 months
|
Duration of Response (DOR)
Time Frame: Up to approximately 51 months
|
For participants who demonstrate confirmed CR or PR per RECIST 1.1 as assessed by BICR, duration of response is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.
CR is defined as the disappearance of all target lesions.
PR is defined as at least a 30% decrease in the sum of diameters of target lesions.
|
Up to approximately 51 months
|
Change From Baseline in the Dyspnea (Item 8) Score, on the EORTC QLQ-C30
Time Frame: Baseline and up to approximately 6 years
|
The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire.
Participant responses to the question "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much).
Using linear transformation, raw scores are standardized so that scores range from 0 to 100.
A higher value indicates increased severity of symptoms.
Change from baseline in dyspnea (EORTC QLQ-C30 Item 8) will be reported.
|
Baseline and up to approximately 6 years
|
Change from Baseline in the Cough (Item 31) Score, on the EORTC Lung-Cancer specific Quality of Life Questionnaire (QLQ-LC13)
Time Frame: Baseline and up to approximately 6 years
|
The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30.
Participant responses to the question "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much).
Using linear transformation, raw scores are standardized, so that scores range from 0 to 100.
A higher value indicates increased severity of symptoms.
Change from baseline in cough (EORTC QLQ-LC13 Item 31) will be reported.
|
Baseline and up to approximately 6 years
|
Change from Baseline in the Chest Pain (Item 40) Score, on the EORTC QLQ-LC13
Time Frame: Baseline and up to approximately 6 years
|
The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30.
Participant responses to the question "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much).
Using linear transformation, raw scores are standardized, so that scores range from 0 to 100.
A higher value indicates increased severity of symptoms.
Change from baseline in chest pain (EORTC QLQ-LC13 Item 40) score will be presented.
|
Baseline and up to approximately 6 years
|
TTD in the Dyspnea (Item 8) Score, on the EORTC QLQ-C30
Time Frame: Baseline and up to approximately 6 years
|
EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients.
Participant responses to the question for Item 8 "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much).
TTD is defined as the time from baseline to the first onset of a ≥10-point decrease from baseline in score.
The TTD in dyspnea score (EORTC QLQ-C30 Item 8) will be reported.
|
Baseline and up to approximately 6 years
|
TTD in the Cough (Item 31) Score, on the EORTC QLQ-LC13
Time Frame: Baseline and up to approximately 6 years
|
The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30.
Participant responses to the question for Item 31 "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much).
TTD is defined as the time from baseline to the first onset of a ≥10-point decrease from baseline in score.
The TTD in cough score (EORTC QLQ-C30 Item 31) will be reported.
|
Baseline and up to approximately 6 years
|
TTD in the Chest Pain (Item 40) Score, on the EORTC QLQ-LC13
Time Frame: Baseline and up to approximately 6 years
|
The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30.
Participant responses to the question for Item 40 "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much).
Using linear transformation, raw scores are standardized, so that scores range from 0 to 100.
TTD is defined as the time from baseline to the first onset of a ≥10-point decrease from baseline in score.
The TTD in chest pain score (EORTC QLQ-C30 Item 40) will be reported.
|
Baseline and up to approximately 6 years
|
Number of Participants Who Experience One or More Adverse Events (AEs)
Time Frame: Up to approximately 6 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
The number of participants who experience one or more AEs will be reported.
|
Up to approximately 6 years
|
Number of Participants Who Discontinue Study Treatment Due to an AE
Time Frame: Up to approximately 6 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
The number of participants who discontinue study treatment due to an AE will be reported.
|
Up to approximately 6 years
|
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Time Frame: Baseline and up to approximately 6 years
|
The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients.
Participant responses to the Global Health Status (GHS) question "How would you rate your overall health during the past week?"
(Item 29) and the Quality of Life (QoL) question "How would you rate your overall quality of life during the past week?"
(Item 30) are scored on a 7-point scale (1=Very Poor to 7=Excellent).
Using linear transformation, raw scores are standardized so that scores range from 0 to 100.
A higher value indicates a better level of function.
The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score will be reported.
|
Baseline and up to approximately 6 years
|
Time to Deterioration (TTD) in Global Health Status/Quality of Life (Items 29 and 30) Combined Score, on the EORTC QLQ-C30
Time Frame: Baseline and up to approximately 6 years
|
EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients.
Participant responses to Items 29 and 30 ("How would you rate your overall health during the past week?"
and "How would you rate your overall quality of life during the past week?")
are scored on a 7-point scale (1=Very Poor to 7=Excellent).
Using linear transformation, raw scores are standardized, so that scores range from 0 to 100.
TTD in Global Health Status (GHS)/Quality of Life (QoL) is defined as the time from baseline to the first onset of a ≥10-point decrease from baseline in combined GHS/QoL score.
The TTD in GHS/QoL (Items 29 and 30) combined score will be reported.
|
Baseline and up to approximately 6 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Medical Director, Merck Sharp & Dohme LLC
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antipyretics
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Histamine Agents
- Folic Acid Antagonists
- Dexamethasone
- Carboplatin
- Acetaminophen
- Pemetrexed
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine H2 Antagonists
Other Study ID Numbers
- 2870-009
- 2023-504910-31 (Registry Identifier: EU CT)
- U1111-1288-3804 (Other Identifier: UTN)
- MK-2870-009 (Other Identifier: Merck)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancer (NSCLC)
-
H. Lee Moffitt Cancer Center and Research InstituteNestle Health ScienceWithdrawnNSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | NSCLC Stage IIIB | Non-small Cell Lung Cancer Stage IIIB | NSCLC, Stage IIIA | Non-small Cell Lung Cancer Stage ⅢAUnited States
-
ElephasBeaufort CRORecruitingNSCLC | Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Metastatic NSCLC - Non-Small Cell Lung CancerUnited States
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
-
Jun Zhang, MD, PhDGenentech, Inc.; ExelixisNot yet recruitingLung Cancer | NSCLC Stage IV | Advanced NSCLC | Metastatic NSCLC - Non-Small Cell Lung CancerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingNSCLC | Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Non-small Cell CarcinomaUnited States
-
University of Alabama at BirminghamSanofiCompletedNon-small Cell Lung Cancer (NSCLC) | Metastatic NSCLC | Stage IV NSCLCUnited States
-
Heather WakeleeNovartis; Genentech, Inc.TerminatedNon-small Cell Lung Cancer (NSCLC), Recurrent | Non-small Cell Lung Cancer (NSCLC), Stage IVUnited States
-
Oslo University HospitalAstraZenecaActive, not recruitingCancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage IIINorway, Finland, Lithuania, Estonia
-
Radiotherapy Oncology Centre "Santa Maria" HospitalPaola Anselmo,MD; Michelina Casale,PhD; Fabio Trippa,MDRecruitingNSCLC | Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Oligometastatic Disease | Non-Small Cell Squamous Lung Cancer | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | Non-Small Cell Adenocarcinoma and other conditionsItaly
-
AmgenParexelWithdrawnMetastatic Non-small Cell Lung Cancer (NSCLC) | Non-squamous NSCLC
Clinical Trials on Antihistamine
-
Johanna Maria VermeulenNanjing University of Chinese Medicine; Mermaid Medicine®Completed
-
Consorci Sanitari de TerrassaInstitut Català de la SalutRecruiting
-
Gachon University Gil Medical CenterHallym University Medical Center; Hallym University Kangnam Sacred Heart Hospital and other collaboratorsRecruitingAllergic RhinitisKorea, Republic of
-
University of CincinnatiUnknownIrritable Bowel Syndrome | Dermatographism | Post-prandial Diarrhea
-
Eisai Co., Ltd.Active, not recruiting
-
China Medical University HospitalCompleted
-
University of OregonRecruitingPostexercise HypotensionUnited States
-
National Institute on Deafness and Other Communication...Completed
-
Goldman, Butterwick, Fitzpatrick and GroffDUSA Pharmaceuticals, Inc.Completed
-
Chulalongkorn UniversityActive, not recruiting